ZUNESTAR 3 Tablet is a pharmaceutical-grade formulation containing Eszopiclone 3 mg, a potent non-benzodiazepine hypnotic indicated for the treatment of insomnia. Eszopiclone is the active S-enantiomer of zopiclone and belongs to the cyclopyrrolone class of sedative agents. It functions by interacting with the GABA-A receptor complex, thereby producing sedative and hypnotic effects that promote sleep onset, improve sleep maintenance, and increase total sleep duration.

The 3 mg strength is considered the highest recommended dose in adult patients who suffer from significant sleep disturbances, including difficulty in falling asleep and repeated nocturnal awakenings. ZUNESTAR 3 is generally administered immediately before bedtime and is especially suitable for patients needing comprehensive sleep management. The formulation is fast-acting, offering sleep induction typically within 30 minutes of ingestion, while its longer duration of action supports uninterrupted sleep through the night.

ZUNESTAR 3 is produced by BluepillExpress in WHO-GMP-certified and ISO-compliant manufacturing units, using precision-engineered processes that ensure high purity, potency, and batch-to-batch consistency. The production process adheres to stringent quality controls and regulatory standards, ensuring the product meets both domestic and international pharmacopoeial specifications. Each tablet is packaged in moisture-resistant blister packaging to ensure stability and shelf life under various climatic conditions.

The pharmacokinetics of Eszopiclone make it a suitable candidate for patients with chronic insomnia. With a half-life of approximately 6 to 7 hours, it ensures that the patient experiences both sleep initiation and maintenance benefits without significant hangover effects the next morning. However, due to its CNS depressant action, it should not be combined with alcohol or other sedatives. ZUNESTAR 3 may cause side effects such as a bitter or metallic aftertaste, dry mouth, headache, dizziness, or mild cognitive slowing in some individuals, especially when taken in higher doses or for prolonged periods.

While Eszopiclone is not a benzodiazepine, it shares similar receptor sites but offers a more selective profile with a reduced risk of dependence and tolerance. ZUNESTAR 3 is generally prescribed for short-term use, although longer durations may be considered under medical supervision for persistent insomnia. It is contraindicated in individuals with hypersensitivity to Eszopiclone or those with severe hepatic impairment, respiratory depression, or a history of substance abuse.

ZUNESTAR 3 is not recommended for pediatric or geriatric populations unless specifically prescribed by a physician, and dose adjustment may be required in such cases. Physicians are advised to assess for underlying causes of insomnia before initiating therapy and to monitor for signs of abuse, tolerance, or withdrawal if used continuously over extended periods.

BluepillExpress offers ZUNESTAR 3 with full third-party manufacturing support, including custom branding, packaging options, regulatory document preparation, and worldwide shipping. Clients are provided with Certificates of Analysis (COA), batch release certificates, and stability data to ensure global compliance and trust. Whether for prescription distribution, institutional supply, or private label brands, ZUNESTAR 3 is crafted to offer market-ready quality with proven therapeutic results.

ZUNESTAR 3 serves as a reliable, evidence-based treatment solution for patients experiencing severe insomnia. With a proven mechanism of action, clinical safety, and effective patient outcomes, it stands as a preferred choice among healthcare providers. As a flagship product from BluepillExpress, ZUNESTAR 3 demonstrates the company’s commitment to innovation, regulatory excellence, and pharmaceutical reliability in every tablet manufactured.